Systematic Review and Meta-analysis

Totally minimally invasive esophagectomy versus hybrid minimally invasive esophagectomy: systematic review and meta-analysis

Frans van Workum,1 Bastiaan R Klarenbeek,1 Nikolaj Baranov,1 Maroeska M Rovers,2 Camiel Rosman1
1Department of Surgery, Radboudumc, Nijmegen, The Netherlands, and 2Department of Health Evidence and Operating Rooms, Radboudumc, Nijmegen, The Netherlands

SUMMARY. Minimally invasive esophagectomy is increasingly performed for the treatment of esophageal cancer, but it is unclear whether hybrid minimally invasive esophagectomy (HMIE) or totally minimally invasive esophagectomy (TMIE) should be preferred. The objective of this study was to perform a meta-analysis of studies comparing HMIE with TMIE. A systematic literature search was performed in MEDLINE, Embase, and the Cochrane Library. Articles comparing HMIE and TMIE were included. The Newcastle–Ottawa scale was used for critical appraisal of methodological quality. The primary outcome was pneumonia. Sensitivity analysis was performed by analyzing outcome for open chest hybrid MIE versus total TMIE and open abdomen MIE versus TMIE separately. Therefore, subgroup analysis was performed for laparoscopy-assisted HMIE versus TMIE, thoracoscopy-assisted HMIE versus TMIE, Ivor Lewis HMIE versus Ivor Lewis TMIE, and McKeown HMIE versus McKeown TMIE. There were no randomized controlled trials. Twenty-nine studies with a total of 3732 patients were included. Studies had a low to moderate risk of bias. In the main analysis, the pooled incidence of pneumonia was 19.0% after HMIE and 9.8% after TMIE which was not significantly different between the groups (RR: 1.46, 95% CI: 0.97–2.20). TMIE was associated with a lower incidence of wound infections (RR: 1.81, 95% CI: 1.13–2.90) and less blood loss (SMD: 0.78, 95% CI: 0.34–1.22) but with longer operative time (SMD: 0.33, 95% CI: −0.59–−0.08). In subgroup analysis, laparoscopy-assisted HMIE was associated with a higher lymph node count than TMIE, and Ivor Lewis HMIE was associated with a lower anastomotic leakage rate than Ivor Lewis TMIE. In general, TMIE was associated with moderately lower morbidity compared to HMIE, but randomized controlled evidence is lacking. The higher leakage rate and lower lymph node count that was found after TMIE in sensitivity analysis indicate that TMIE can also have disadvantages. The findings of this meta-analysis should be considered carefully by surgeons when moving from HMIE to TMIE.

KEY WORDS: esophageal cancer, totally minimally invasive esophagectomy, hybrid minimally invasive esophagectomy.

INTRODUCTION

Esophagectomy is the cornerstone for curative treatment of esophageal cancer. Open esophagectomy is increasingly being replaced by minimally invasive esophagectomy (MIE). Currently it is estimated that nearly 45% of patients are operated using a minimally invasive approach worldwide.1 MIE can be performed by hybrid minimally invasive esophagectomy (HMIE, laparotomy and thoracoscopy or laparoscopy and thoracotomy) or totally minimally invasive esophagectomy (TMIE, laparoscopy and thoracoscopy). In the Western world, laparoscopy-assisted HMIE is increasingly replaced by TMIE, in an attempt to further decrease postoperative morbidity without compromising patients’ safety.1 Systematic reviews of retrospective studies comparing the results of open esophagectomy to TMIE and open esophagectomy to HMIE have found that both HMIE and TMIE have advantages over the open approach in terms of blood loss, length of stay, and pulmonary complications.2,3 In addition, these positive effects of MIE have been shown in a randomized controlled trial for HMIE4 and for TMIE.5 Because these beneficial effects seem to be comparable between HMIE and TMIE in these randomized controlled trials, HMIE and TMIE are currently considered to be surgical techniques with equivalently beneficial outcomes. However, no randomized controlled trials have compared HMIE and TMIE and no meta-analysis comparing HMIE and TMIE have been performed.
Therefore, the aim of this article was to perform a systematic review and meta-analysis of studies comparing HMIE with TMIE in patients undergoing esophagectomy.

MATERIALS AND METHODS

Literature search

The review protocol is registered in the PROSPERO international prospective register of systematic reviews (number CRD 42016043291). PRISMA guidelines for systematic reviews were followed, and the PRISMA checklist is available in online Appendix I.

The electronic databases of MEDLINE, Embase, and the Cochrane central register of controlled trials were systematically searched. The search strategy was composed in collaboration with a medical librarian, and the exact (MEDLINE) search strategy was (minimal invasive[tiab] OR minimally invasive[tiab] OR laparo-thoracoscop*[tiab] OR laparothoracoscop*[tiab] OR thoraco-laparoscop*[tiab] OR laparoscop*[tiab] OR hybrid[tiab] OR VATS[tiab] OR video-assisted[tiab] OR video assisted[tiab] OR thoracolaparoscop*[tiab] OR thoracoscop*[tiab] OR esophagectom*[tiab] OR oesophagectom*[tiab] OR resection*[tiab] AND (oesophageal[tiab] OR esophageal[tiab] OR esophagus[tiab] OR esophageal[tiab] OR oesophagus[tiab] OR esophageal[tiab] OR oesophagus[tiab] OR esophagus[tiab] OR esophageal[tiab] OR esophagus[tiab] OR esophageal[tiab])). A cited reference search and hand search were additionally performed. No language restrictions were applied and all results up to April 2019 were included.

Criteria for selecting studies for this review

Comparative cohort studies or randomized controlled trials comparing patients undergoing HMIE versus TMIE were included. We suspected that articles on ‘outcome after MIE’ could contain data on both HMIE and TMIE without this being explicitly described in the abstract. Therefore, we liberally included abstracts that contained outcome data after any form of MIE for full text screening.

Exclusion criteria were less than 10 patients per treatment arm and unclear description of operative technique rendering classification into HMIE or TMIE impossible. Studies that incorporated results of a transhiatal approach in the TMIE group were also excluded, because transhiatal resection cannot be performed as a hybrid procedure and inclusion would therefore be a source of selection bias. Video-assisted thoracic surgery (VATS) procedures and hand-assisted laparoscopic surgery (HALS) procedures were classified as minimally invasive and were also included.

Articles were selected for inclusion using a three-step review process. First, the titles and abstracts of all identified studies were examined by three reviewers (FvW, BK, and NB) independently, and studies that failed to meet the inclusion criteria were excluded. Second, reviewers (FvW, BK, and NB) independently examined the full text of potentially relevant articles. In the event of disagreement regarding the eligibility of a study during this phase, the opinion of a fourth reviewer (CR) was sought, and the parameters of the study’s inclusion were discussed until consensus was reached. Third, all articles cited in and cited by the remaining eligible and relevant articles were independently assessed for inclusion.

Quality assessment

The Newcastle–Ottawa quality assessment scale was used to assess bias in studies included in this review. This scale rates studies on three sources of bias based on eight criteria. Each criterion is worth one star except confounding, which is worth two stars. For this systematic review, studies scoring seven to nine stars were considered to be of high methodological quality, studies scoring four to six stars were considered to be of moderate methodological quality, and studies scoring one to three stars were considered to be of low methodological quality.

Outcome parameters and data extraction

The primary outcome parameter was pneumonia. Secondary outcome parameters were all complications, severe complications (Clavien–Dindo > 2), pulmonary complications, anastomotic leakage, chyle leakage, RLN palsy, wound infection, reoperation, hospital length of stay, ICU length of stay, postoperative mortality, operating time, blood loss, R0 resection rate, number of lymph nodes, and quality of life. Data was extracted and was entered into Review Manager (version 5.3).

In case continuous variables were expressed as median and interquartile range or range, the mean and SD were estimated from the available data by methods described elsewhere.

Analysis

Since studies were homogeneous enough to pool, meta-analyses were performed, and statistical heterogeneity was assessed. The Mantel–Haenszel method was used for dichotomous data, presented as relative risks (RR) with 95% confidence intervals (CIs). The inverse variance method was used for meta-analysis of continuous data; results are presented as standardized mean difference (SMD) with 95% CIs. A random effects model was used for all analyses. The statistical heterogeneity was assessed with $I^2$. A funnel plot with the effect measures on the x-axis and standard error
of the log for the effect measures on the y-axis was created for the primary outcome parameter in order to assess publication bias.

In addition to comparing all articles reporting on outcome of patients undergoing HMIE versus TMIE, subgroup and sensitivity analyses were performed for (i) laparoscopy-assisted HMIE (minimally invasive abdominal phase and open thoracic phase) versus TMIE; (ii) thoracoscopy-assisted HMIE (minimally invasive thoracic phase and open abdominal phase) versus TMIE; (iii) Ivor Lewis HMIE versus Ivor Lewis TMIE; and (iv) McKeown HMIE versus McKeown TMIE. For the Ivor Lewis HMIE group, we decided to only include the Ivor Lewis laparoscopy-assisted HMIE (therefore excluding one study that compared Ivor Lewis thoracoscopy-assisted HMIE with Ivor Lewis TMIE), since this reflects the predominant change of practice that is currently taking place in the Western world.

RESULTS

Studies
Twenty-nine studies, including a total of 3,732 patients, met the inclusion criteria of this systematic review. A summary of the screening and selection process is shown in Figure 1. The individual studies included 29-445 patients. In 14 studies (n = 1,631) laparoscopy-assisted HMIE was compared to TMIE;
Quality and publication bias assessment

There were no randomized controlled trials. Studies scored six to nine stars out of nine according to the Newcastle–Ottawa rating scale, corresponding to a moderate to low risk of bias for non-randomized studies. The results of the quality assessment of the included studies are summarized in Table 1.

Meta-analysis of all included studies comparing all HMIE with TMIE

A total of 15 studies including 1,492 patients reported the incidence of the primary outcome parameter. The pooled incidence of pneumonia was 19.0% after HMIE and 9.8% after TMIE which was not significantly different between the groups (RR: 1.46, 95% CI: 0.97–2.20). In a post hoc sensitivity analysis in which we excluded studies that included patients with HALS or VATS, these results remained similar (RR: 1.26, 95% CI: 0.85–1.89). Compared to HMIE, TMIE was associated with a lower incidence of wound infections (RR: 1.81, 95% CI: 1.13–2.90) and less blood loss (SMD: 0.78, 95% CI: 0.34–1.22) but with a longer operative time (SMD: -0.33, 95% CI: -0.59 to -0.08) (Appendix IV-a). The other parameters were not statistically different between the groups (Table 2).

Subgroup analyses per resection type

In the Ivor Lewis HMIE versus TMIE subgroup, the incidence of pneumonia was described by four studies (n = 297) and was not statistically different between the groups (RR: 1.83, 95% CI: 0.71–4.71). Compared to Ivor Lewis HMIE, Ivor Lewis TMIE was associated with a lower incidence of wound infections (RR: 7.33, 95% CI: 1.39–38.61) and less blood loss (SMD: 0.66, 95% CI: 0.36–0.95), but with a longer operative time (SMD: -0.47, 95% CI: -0.72 to -0.23). Anastomotic leakage was reported in seven studies (n = 723), and the pooled incidence was 10.0% after Ivor Lewis HMIE compared to 18.9% after Ivor Lewis TMIE (RR: 0.55, 95% CI: 0.38–0.80) (Table 5) (Appendix IV-d).

In the McKeown HMIE versus McKeown TMIE subgroup, the incidence of pneumonia was reported by 8 studies which included 947 patients. The incidence of pneumonia did not differ between the groups (RR: 1.45, 95% CI: 0.84–2.54). Compared to McKeown HMIE, McKeown TMIE was associated with a lower incidence of pulmonary complications (RR: 1.45, 95% CI: 1.05–1.99), less blood loss (SMD: 1.11, 95% CI: 0.46–1.75), and a shorter hospital length of stay (SMD: 0.38, 95% CI: 0.09–0.66) (Table 6) (Appendix IV-e).

DISCUSSION

This meta-analysis showed that a clinically relevant difference in the incidence of pneumonia between HMIE and TMIE might exist, but we were unable to demonstrate this since this difference did not reach statistical significance. Interestingly, in the subgroup analysis in which different types of HMIE were compared to TMIE, the incidence of pneumonia was lower after TMIE when it was compared with laparoscopy-assisted HMIE but not when it was compared with thoracoscopy-assisted HMIE. Although laparoscopy-assisted HMIE has clearly been shown to reduce pulmonary complications, this finding may implicate that a further reduction of postoperative pneumonia is possible by moving from laparoscopy-assisted HMIE to TMIE. In general,
| Study | Design | N | Type of HMIE | Surgery type TMIE | Outcome parameters |
|-------|--------|---|--------------|------------------|--------------------|
| Berlth 2018 | Retrospective cohort | 60 | LA; laparoscopy | Laparoscopy and Ivor Lewis | Pneumonia, pulm complications, AL, severe compl, all compl, RLN palsy, mortality, R0, WI, LC, IU, thoracoscopy |
| Blazeby 2011 | Prospective cohort | 124 | LA; laparoscopy | Laparoscopy and McKeown | Severe compl, reoperation, chyle leak, mortality, hosp LOS, LN, OT, blood loss |
| Bonavina 2016 | Retrospective cohort, PSMA | 160 | LA; laparoscopy | Thoracoscopy | Severe compl, reoperation, chyle leak, mortality, hosp LOS, LN, OT, blood loss |
| Daiko 2015 | Cohort (not specified) | 64 | TA; thoracoscopy | Laparoscopy and McKeown | All compl, pneumonia, pulm complications, AL, chyle leak, RLN palsy, mortality, R0, WI, thoracoscopy |
| Elshaer 2017 | Prospective cohort | 26 | LA; laparoscopy | Laparoscopy and Ivor Lewis | AL, chyle leak, mortality, hosp LOS, LN, OT |
| Findlay 2017 | Prospective cohort | 162 | LA; laparoscopy | Laparoscopy and McKeown | AL, mortality, hosp LOS, LN, OT |
| Fumagalli 2019 | Prospective cohort | 349 | LA; laparoscopy | Thoracoscopy | AL, chyle leak, mortality, hosp LOS, LN, OT, blood loss |
| Grimminger 2018 | Prospective cohort | 50 | LA; laparoscopy | Laparoscopy and Ivor Lewis | Pneumonia, AL, reoperation, chyle leak, mortality, R0, WI, thoracoscopy |
| Hamouda 2010 | Prospective cohort | 51 | LA; laparoscopy | Laparoscopy and VATS | Pneumonia, AL, reoperation, chyle leak, mortality, thoracoscopy |
| Ichikawa 2013 | Prospective cohort | 315 | TA; thoracoscopy | HALS and thoracoscopy | All compl, pneumonia, pulm complications, AL, chyle leak, RLN palsy, mortality, R0, ICU LOS, LN, OT, blood loss |
| Kinjo 2012 | Cohort (not specified) | 106 | TA; thoracoscopy | HALS and thoracoscopy | All compl, pneumonia, pulm complications, AL, chyle leak, RLN palsy, mortality, R0, ICU LOS, LN, OT, blood loss |
| Kitagawa 2016 | Retrospective cohort | 105 | LA; laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Kubo 2014 | Prospective cohort | 59 | LA; laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Le 2011 | Prospective cohort | 135 | TA; VATS | HALS and VATS | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Le 2015 | Prospective cohort | 98 | TA; VATS | HALS and VATS | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Lin 2017 | Prospective cohort | 172 | LA; laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Lin 2015 | Retrospective cohort | 36 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Ma 2015 | Prospective cohort | 56 | LA; & TA laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Martin 2005 | Prospective cohort | 59 | LA; laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Nakagawa 2017 | Prospective cohort | 101 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Nakao 2015 | Retrospective cohort | 80 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Nozaki 2017 | Prospective cohort | 94 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Oshikiri 2016 | Prospective cohort | 64 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Osako 2016 | Prospective cohort | 45 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Safranek 2010 | Prospective cohort | 75 | LA & TA laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Sanno 2007 | Prospective cohort | 322 | LA; laparoscopy | Laparoscopy and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Showaki 2019 | Prospective cohort | 137 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Tiwag 2007 | Prospective cohort | 49 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Yano 2017 | Prospective cohort | 29 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |
| Yano 2018 | Prospective cohort | 131 | TA; thoracoscopy | HALS and thoracoscopy | Pulm compl, AL, RLN palsy, mortality, WI, ICU LOS, hosp LOS, LN, OT, blood loss |

**Note:** TMIE, totally minimally invasive esophagectomy; HMIE, hybrid minimally invasive esophagectomy; LA, laparoscopic assisted (thus; minimally invasive abdominal and open thoracic stage); TA, thoracoscopic assisted (thus; minimally invasive thoracic and open abdominal stage); PSMA, propensity score matched analysis; VATS, video-assisted thoracic surgery; complication; PAL, pulmonary complications; AL, anastomotic leakage; R0, R0 resection rate; WI, wound infection; ICU, intensive care unit; LOS, length of stay; LN, lymph node examined; OT, operating time.
Table 2  All hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

| Parameter                  | No of studies | No of patients | RR/SMD (95% CI) | I² (%) |
|----------------------------|---------------|----------------|-----------------|-------|
| Pneumonia (RR)             | 15            | 1492           | 1.46 (0.97–2.20) | 39    |
| Pulmonary complications (RR)| 18            | 2653           | 1.24 (0.97–1.58) | 31    |
| Anastomotic leakage (RR)   | 27            | 3572           | 0.94 (0.73–1.21) | 32    |
| Chyle leakage (RR)         | 13            | 1641           | 1.13 (0.62–2.04) | 0     |
| RLN palsy (RR)             | 16            | 2035           | 0.90 (0.65–1.25) | 22    |
| Wound infection (RR)       | 11            | 1003           | 1.81 (1.13–2.90) | 0     |
| Severe complications (RR)  | 5             | 654            | 0.95 (0.72–1.25) | 24    |
| All complications (RR)     | 9             | 1643           | 1.10 (0.99–1.23) | 0     |
| Reoperation (RR)           | 7             | 703            | 0.86 (0.51–1.46) | 0     |
| Postoperative mortality (RR)| 24           | 2951           | 1.33 (0.73–2.41) | 38    |
| Irradical resection (RR)   | 13            | 2066           | 1.22 (0.93–1.60) | 0     |
| Intensive care LOS (SMD)   | 12            | 1490           | 0.19 (0.00–0.38) | 59    |
| Hospital LOS (SMD)         | 23            | 2699           | 0.19 (0.00–0.39) | 79    |
| Extracted lymph nodes (SMD)| 19            | 2630           | –0.01 (–0.24–0.22) | 85    |
| Operating time (SMD)       | 23            | 2782           | –0.33 (–0.59–0.08) | 88    |
| Blood loss (SMD)           | 71            | 2701           | 0.78 (0.34–1.22) | 96    |

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR > 1 favors TMIE and RR < 1 favors HMIE. For continuous parameters, SMD > 0 favors TMIE and SMD < 0 favors HMIE, except for the parameter ‘Extracted lymph nodes’, in which SMD > 0 favors HMIE and SMD < 0 favors TMIE.

Table 3  Laparoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

| Parameter                  | No of studies | No of patients | RR/SMD (95% CI) | I² (%) |
|----------------------------|---------------|----------------|-----------------|-------|
| Pneumonia (RR)             | 6             | 451            | 1.86 (1.03–3.37) | 9     |
| Pulmonary complications (RR)| 9             | 889            | 1.15 (0.78–1.71) | 44    |
| Anastomotic leakage (RR)   | 14            | 1581           | 0.79 (0.57–1.11) | 30    |
| Chyle leakage (RR)         | 5             | 521            | 1.10 (0.48–2.53) | 0     |
| RLN palsy (RR)             | 6             | 646            | 0.68 (0.35–1.35) | 23    |
| Wound infection (RR)       | 5             | 501            | 1.69 (0.96–2.96) | 0     |
| Severe complications (RR)  | 5             | 654            | 0.95 (0.72–1.25) | 24    |
| All complications (RR)     | 4             | 381            | 1.00 (0.82–1.22) | 0     |
| Reoperation (RR)           | 5             | 522            | 0.79 (0.43–1.46) | 0     |
| Postoperative mortality (RR)| 12           | 1132           | 1.28 (0.61–2.67) | 0     |
| Irradical resection (RR)   | 6             | 620            | 1.44 (0.69–2.29) | 0     |
| Intensive care LOS (SMD)   | 7             | 633            | 0.28 (0.06–0.61) | 75    |
| Hospital LOS (SMD)         | 12            | 1082           | 0.16 (0.08–0.39) | 69    |
| Extracted lymph nodes (SMD)| 10            | 898            | 0.29 (0.10–0.49) | 47    |
| Operating time (SMD)       | 11            | 920            | –0.50 (–0.74––0.25) | 65    |
| Blood loss (SMD)           | 9             | 844            | 0.39 (0.07–0.72) | 79    |

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR > 1 favors TMIE and RR < 1 favors HMIE. For continuous parameters, SMD > 0 favors TMIE and SMD < 0 favors HMIE, except for the parameter ‘Extracted lymph nodes’, in which SMD > 0 favors HMIE and SMD < 0 favors TMIE.

Parameters regarding postoperative morbidity showed moderately improved outcome after TMIE compared to HMIE. However, we additionally found that anastomotic leakage was higher after Ivor Lewis TMIE compared to Ivor Lewis HMIE and that laparoscopy-assisted HMIE was associated with higher numbers of extracted lymph nodes compared to TMIE, and this suggests that TMIE can also have disadvantages regarding clinically important outcome parameters.

The major strength of this systematic review and meta-analysis is that this is the first study that directly compares the effectiveness of HMIE with TMIE. Some possible limitations should also be discussed. First, although statistical heterogeneity was limited, supporting our decision to pool results of the included studies in a meta-analysis, clinical heterogeneity (i.e. variations in surgical technique of HMIE and TMIE) was present. The variations in surgical technique of the included studies reflect the current lack of robust evidence on the optimal surgical technique for resection of esophageal cancer. In order to address this, we performed subgroup-and sensitivity analyses for which we included studies that only compared similar types of surgery, and this indeed resulted in lower heterogeneity for most parameters. Additionally, there was heterogeneity in our primary outcome parameter definition across studies. Second, selection bias could not be excluded since TMIE was most frequently implemented after HMIE and compared retrospectively, possibly favoring outcome in the TMIE group. However, the fact that the anastomotic leakage rate was higher after TMIE cannot be explained by this type of selection bias.
Table 4 Thoracoscopy-assisted hybrid minimally invasive esophagectomy versus totally minimally invasive esophagectomy

| Condition                  | No of studies | No of patients | RR/SMD (95% CI) | I² (%) |
|----------------------------|---------------|----------------|-----------------|--------|
| Pneumonia (RR)             | 8             | 966            | 1.24 (0.66–2.34) | 57     |
| Pulmonary complications (RR)| 8             | 1319           | 1.33 (0.95–1.86) | 30     |
| Anastomotic leakage (RR)   | 10            | 1412           | 1.28 (0.81–2.03) | 29     |
| Chyle leakage (RR)         | 6             | 1120           | 1.16 (0.50–2.69) | 0      |
| RLN palsy (RR)             | 9             | 1314           | 1.16 (0.92–1.45) | 0      |
| Wound infection (RR)       | 5             | 502            | 2.13 (0.88–5.14) | 0      |
| Severe complications (RR)  | 0             | 0              | N/A             | N/A    |
| All complications (RR)     | 4             | 817            | 1.16 (1.02–1.32) | 0      |
| Reoperation (RR)           | 1             | 106            | 3.18 (0.56–18.14)| N/A    |
| Postoperative mortality (RR)| 9             | 1240           | 1.34 (0.36–5.08) | 12     |
| Irradical resection (RR)   | 5             | 926            | 0.90 (0.57–1.42) | 0      |
| Intensive care LOS (SMD)   | 4             | 782            | 0.17 (0.00–0.34) | 0      |
| Hospital LOS (SMD)         | 9             | 1097           | 0.31 (–0.12–0.74) | 88     |
| Extracted lymph nodes (SMD)| 7             | 1212           | –0.37 (–0.81–0.07)| 91     |
| Operating time (SMD)       | 10            | 1342           | 0.21 (–0.65–0.23) | 91     |
| Blood loss (SMD)           | 10            | 1412           | 1.03 (0.31–1.75) | 97     |

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR > 1 favors TMIE and RR < 1 favors HMIE. For continuous parameters, SMD > 0 favors TMIE and SMD < 0 favors HMIE, except for the parameter ‘Extracted lymph nodes’, in which SMD > 0 favors HMIE and SMD < 0 favors TMIE.

Table 5 Laparoscopy-assisted hybrid minimally invasive Ivor Lewis esophagectomy versus totally minimally invasive Ivor Lewis esophagectomy

| Condition                  | No of studies | No of patients | RR/SMD (95% CI) | I² (%) |
|----------------------------|---------------|----------------|-----------------|--------|
| Pneumonia (RR)             | 4             | 297            | 1.83 (0.71–4.71) | 32     |
| Pulmonary complications (RR)| 4             | 298            | 1.45 (0.98–2.15) | 4      |
| Anastomotic leakage (RR)   | 7             | 723            | 0.55 (0.38–0.80) | 0      |
| Chyle leakage (RR)         | 4             | 177            | 1.05 (0.21–5.28) | 0      |
| RLN palsy (RR)             | 2             | 197            | 4.18 (0.52–33.57)| 0      |
| Wound infection (RR)       | 2             | 187            | 7.33 (1.39–38.61)| 0      |
| Severe complications (RR)  | 2             | 197            | 0.85 (0.57–1.27) | 0      |
| All complications (RR)     | 2             | 197            | 1.02 (0.79–1.32) | 0      |
| Reoperation (RR)           | 3             | 238            | 2.21 (0.44–11.06)| 0      |
| Postoperative mortality (RR)| 5             | 323            | 0.85 (0.17–4.19) | 0      |
| Irradical resection (RR)   | 4             | 298            | 1.63 (0.39–6.73) | 0      |
| Intensive care LOS (SMD)   | 2             | 110            | 0.45 (–0.77–1.67)| 89     |
| Hospital LOS (SMD)         | 4             | 273            | –0.05 (–0.31–0.21)| 9      |
| Extracted lymph nodes (SMD)| 4             | 273            | 0.17 (–0.09–0.42)| 6      |
| Operating time (SMD)       | 4             | 273            | –0.47 (–0.72–0.23)| 0      |
| Blood loss (SMD)           | 2             | 197            | 0.66 (0.36–0.95) | 0      |

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR > 1 favors TMIE and RR < 1 favors HMIE. For continuous parameters, SMD > 0 favors TMIE and SMD < 0 favors HMIE, except for the parameter ‘Extracted lymph nodes’, in which SMD > 0 favors HMIE and SMD < 0 favors TMIE.

since TMIE cases were generally operated on in later time frames. In addition, TMIE has been described to be associated with a significant learning curve, and this might favor outcome in the HMIE group.41–44 Finally, the Newcastle–Ottawa rating scale was used because high-quality randomized studies were absent. Although this score gives a relevant indication of the quality of non-randomized studies, it generally results in an overestimation of the quality of the included studies, and this should be taken into account when interpreting the results of this study.

Currently, no RCTs have been performed that compared the effectiveness of HMIE versus TMIE, and as far as we are aware, no RCTs are currently being performed on this subject. Although the ROMIO feasibility trial has randomized between open, laparoscopy-assisted HMIE and TMIE, this feasibility study was not designed to identify a difference between HMIE and TMIE,45 and the definitive ROMIO trial does not randomize patients between open esophagectomy and laparoscopy-assisted HMIE.46 Therefore, surgeons will have to rely on non-randomized data when making decisions regarding whether to use HMIE or TMIE for surgical resection of esophageal cancer. The current meta-analysis provides an overview of the best available evidence on differences in outcome of HMIE compared to TMIE. From our data, TMIE was generally associated with a (trend towards) lower postoperative morbidity compared to HMIE. This suggests that TMIE has potential benefits over HMIE regarding morbidity. However, anastomotic leakage was higher after Ivor Lewis TMIE compared to Ivor Lewis HMIE. This may be explained by a
Table 6  Hybrid minimally invasive McKeown esophagectomy versus totally minimally invasive McKeown esophagectomy

|                          | No of studies | No of patients | RR/SMD (95% CI) | I² (%) |
|--------------------------|---------------|----------------|-----------------|--------|
| Pneumonia (RR)           | 8             | 947            | 1.46 (0.84–2.54) | 52     |
| Pulmonary complications (RR) | 9            | 1774           | **1.45 (1.05–1.99)** | 21     |
| Anastomotic leakage (RR) | 14            | 2106           | 1.26 (0.93–1.72) | 19     |
| Chyle leakage (RR)       | 7             | 1255           | 1.14 (0.58–2.25) | 0      |
| RLN palsy (RR)           | 11            | 1528           | 0.82 (0.56–1.22) | 36     |
| Wound infection (RR)     | 6             | 607            | 1.65 (0.98–2.78) | 0      |
| Severe complications (RR) | 0             | 0              | N/A             | 0      |
| All complications (RR)   | 6             | 1397           | 1.13 (1.00–1.27) | 0      |
| Reoperation (RR)         | 2             | 181            | 1.25 (0.25–6.28) | 55     |
| Postoperative mortality (RR) | 13     | 1934           | 1.74 (0.68–4.48) | 0      |
| Irradical resection (RR) | 7             | 1446           | 1.12 (0.81–1.57) | 0      |
| Intensive care LOS (SMD) | 8             | 1171           | 0.12 (–0.02–0.26) | 7      |
| Hospital LOS (SMD)       | 12            | 1732           | **0.38 (0.09–0.66)** | 83     |
| Extracted lymph nodes (SMD) | 9          | 1712           | –0.18 (–0.46–0.10) | 83     |
| Operating time (SMD)     | 13            | 1977           | –0.26 (–0.62–0.10) | 91     |
| Blood loss (SMD)         | 12            | 1972           | **1.11 (0.46–1.75)** | 83     |

RR, relative risk; SMD, standardized mean difference; CI, confidence interval. For dichotomous parameters, RR > 1 favors TMIE and RR < 1 favors HMIE. For continuous parameters, SMD > 0 favors TMIE and SMD < 0 favors HMIE, except for the parameter ‘Extracted lymph nodes’, in which SMD > 0 favors HMIE and SMD < 0 favors TMIE.

surgical learning curve, which has been described to be long for Ivor Lewis TMIE (>100 cases, which can correspond to years of practice), since intrathoracic anastomosis can be difficult to perform safely with minimally invasive techniques. Although no studies have been published that directly compare learning curves of HMIE and TMIE, it is assumed that HMIE is associated with a shorter learning curve and less associated morbidity because it is technically less complex. However, literature also shows that favorable results of TMIE can be achieved after the learning curve has been completed, but this might not have been the case in most included studies. Another important finding is that laparoscopy-assisted HMIE was associated with higher numbers of extracted lymph nodes compared to TMIE. This suggests that surgeons performing thoracoscopic instead of open thoracic resection performed a more limited lymph node dissection, although other factors (e.g. pathology department related) may have also influenced lymph node count. In general, higher lymph node count is associated with improved survival after esophagectomy, and this is therefore an important finding. However, similar rates of extracted lymph nodes after minimally invasive versus open surgery and even higher numbers of extracted lymph nodes after thoracoscopic versus open transthoracic resection have been reported.

Clinical implications
Currently, HMIE and TMIE are regarded as equally effective, and safe surgical approaches and both procedures are used to treat patients with esophageal cancer worldwide. In this meta-analysis, a moderate benefit for TMIE regarding morbidity was found. Because outcomes between HMIE and TMIE are only moderately different, the learning curve of HMIE and TMIE procedures and its associated morbidity may also be important arguments in choosing which type of procedure to implement. Therefore, surgeons moving from HMIE to TMIE should carefully consider this, since this study showed that TMIE can also have disadvantageous effects and randomized controlled evidence supporting the benefits of TMIE over HMIE is lacking.

CONCLUSIONS
In general, TMIE was associated with moderately lower morbidity compared to HMIE, but randomized controlled evidence is lacking. The higher leakage rate and lower lymph node count that was found after TMIE in sensitivity analysis indicate that TMIE can also have disadvantageous effects. The findings of this meta-analysis should be considered carefully by surgeons when moving from HMIE to TMIE.

DETAILS OF CONTRIBUTIONS
All authors contributed to the design of the work; F. Van Workum and B.R. Klarenbeek and N. Baranov were involved in acquisition of the data. Analysis was performed by F. van Workum, and all other authors were involved in interpretation of the work. F. Van Workum and B.R. Klarenbeek were involved in drafting the manuscript. All other authors were involved in critically revising the manuscript for intellectual content. All authors approve of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
ACKNOWLEDGEMENTS

None.

No funds were received in support of this study.
No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

References

1 Haverkamp L, Seessing M F, Ruurda J P et al. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus 2017; 30: 1–7.
2 Nagpal K, Ahmed K, Vats A et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc 2010; 24: 1621–9.
3 Xiong W L, Li R, Lei H K et al. Comparison of outcomes between minimally invasive oesophagectomy and open oesophagectomy for oesophageal cancer. ANZ J Surg 2017; 87: 165–70.
4 Mariette C, Markar S R, Dabakuyo-Yonli T S et al. Hybrid minimally invasive esophagectomy for Esophageal cancer. ANZ J Surg 2017; 87: 165–70.
5 Biere S S, van Berge Henegouwen M I, Maas K W et al. Outcomes of hybrid minimally invasive esophagectomy for esophageal carcinoma reduces postoperative pain and pneumonia compared to hybrid esophagectomy. Surg Endosc 2018; 32: 4957–65. doi: 10.1007/s00464-018-6257-2 Epub 2018 Jun 21.
6 Daiko H, Fujita T. Laparoscopic assisted versus open gastric pull-up following thoracoscopic esophagectomy: a cohort study. Int J Surg 2015; 19: 61–6.
7 Elshaer M, Gravante G, Tang C B, Jayanthi N V. Totally minimally invasive two-stage esophagectomy with intrathoracic hand-sewn anastomosis: short-term clinical and oncological outcomes. Dis Esophagus 2018; 1: 31. doi: 10.1093/dote/-dco150.
8 Findlay L, Yao C, Bennett D H, Byrom R, Davies N. Non-inferiority of minimally invasive oesophagectomy: an 8-year retrospective case series. Surg Endosc 2017; 31: 3681–9. doi: 10.1007/s00464-016-5406-8 Epub 2017 Jan 11.
9 Fumagalli U, Basiochet G L, Celotti A et al. Incidence and treatment of mediastinal leakage after esophagectomy: insights from the multicenter study on mediastinal leaks. World J Gastroenterol 2019; 25: 356–66. doi: 10.3748/wjg.v25.i3.356.
10 Grimmer P P, Tagkalos E, Hadzijusufovic E et al. Change from hybrid to fully minimally invasive and robotic Esophagectomy is possible without compromises. Thorac Cardiovasc Surg 2018; doi: 10.1055/s-0038-1670664 [Epub ahead of print].
11 Hamouda A H, Forshaw M J, Tsigritis K et al. Effectiveness of combined thoracoscopic-laparoscopic esophagectomy: comparison of postoperative complications and midterm oncological outcomes in patients with esophageal cancer. Surg Endosc 2012; 26: 381–90.
12 Ichikawa H, Miyata G, Miyazaki S et al. Esophagectomy using a thoracoscopic approach with an open laparotomic or hand-assisted laparoscopic abdominal stage for esophageal cancer: analysis of survival and prognostic factors in 315 patients. Ann Surg 2013; 257: 873–85.
13 Kinjo Y, Kurita N, Nakamura F et al. Effectiveness of combined thoracoscopic-laparoscopic esophagectomy: comparison of postoperative complications and midterm oncological outcomes in patients with esophageal cancer. Surg Endosc 2012; 26: 381–90.
14 Kitagawa H, Namikawa T, Munekage M et al. Outcomes of thoracoscopic esophagectomy in prone position with laparoscopic gastric mobilization for esophageal cancer. Langenbecks Arch Surg 2016; 401: 699–705.

Fig. 2 All hybrid minimally invasive esophagectomy (HMIE) versus totally minimally invasive esophagectomy (TMIE) for primary outcome parameter pneumonia.
25 Kubo N, Ohira M, Yamashita Y et al. The impact of combined thoracoscopic and laparoscopic surgery on pulmonary complications after radical esophagectomy in patients with resectable esophageal cancer. Anticancer Res 2014; 34: 2399–404.

26 Lee J M, Cheng J W, Lin M T et al. Is there any benefit to incorporating a laparoscopic procedure into minimally invasive esophagectomy? The impact on perioperative results in patients with esophageal cancer. World J Surg 2011; 35: 790–7.

27 Lee J W, Sung S W, Park J K et al. Laparoscopic gastric tube formation with pyloromyotomy for reconstruction in patients with esophageal cancer. Ann Surg Treat Res 2015; 89: 117–23.

28 Li K K, Wang Y J, Liu X H et al. Propensity-matched analysis comparing survival after hybrid Thoracoscopic-laparotomy Esophagectomy and complete Thoracoscopic-laparoscopic Esophagectomy. World J Surg 2019; 43: 853–61. doi: 10.1007/s00268-018-4843-z.

29 Mao T, Fang W, Gu Z et al. Comparison of perioperative outcomes between open and minimally invasive esophagectomy for esophageal cancer. Thorac Cancer 2015; 6: 303–6.

30 Martin D J, Bessell J R, Chew A et al. Thoracoscopic and laparoscopic esophagectomy: initial experience and outcomes. Surg Endosc 2005; 19: 1597–601.

31 Mu J W, Gao S G, Xue Q et al. Updated experiences with minimally invasive McKeown esophagectomy for esophageal cancer. World J Gastroenterol 2015; 21: 12873–81.

32 Nilsson M, Kamiya S, Lindblad M, Rouvelas I. Implementation of minimally invasive esophagectomy in a tertiary referral center for esophageal cancer. J Thorac Dis 2017; 9: S817–25. doi: 10.21037/jtd.2017.04.23.

33 Nozaki I, Mizusawa J, Kato K et al. Impact of laparoscopy on the prevention of pulmonary complications after thoracoscopic esophagectomy using data from JCOG0502: a prospective multicenter study. Surg Endosc 2018; 32: 651–9. doi: 10.1007/s00464-017-5716-5 Epub 2017 Aug 4.

34 Oshikiri T, Yasuda T, Kawasaki K et al. Hand-assisted laparoscopic surgery (HALS) is associated with less-restrictive ventilatory impairment and less risk for pulmonary complication than open laparotomy in thoracoscopic esophagectomy. Surgery 2016; 159: 459–66.

35 Safranek P M, Cubit J, Booth M I et al. Review of open and minimal access approaches to oesophagectomy for cancer. Br J Surg 2010; 97: 1845–53.

36 Smithers B M, Gotley D C, Martin I et al. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007; 245: 232–40.

37 Souche R, Nayeri M, Chati R et al. Thoracoscopic in prone position with two-lung ventilation compared to conventional thoracotomy during Ivor Lewis procedure: a multicenter case-control study. Surg Endosc 2019. doi: 10.1007/s00464-019-06742-w [Epub ahead of print].

38 Tsujimoto H, Takahata R, Nomura S et al. Video-assisted thoracoscopic surgery for esophageal cancer attenuates postoperative systemic responses and pulmonary complications. Surgery 2012; 151: 667–73.

39 Yanasoot A, Yoshuriyawong K, Ruangsin S, Loahawiriyakamol S, Sunpaweravong S. Costs and benefits of different methods of esophagectomy for esophageal cancer. Asian Cardiovasc Thorac Ann 2017; 25: 513–7. doi: 10.1177/0218492317137339 Epub 2017 Sep 5.

40 Yao F, Wang J, Yao J et al. Is thoracoscopic-laparoscopic esophagectomy a better alternative to thoracoscopic esophagectomy? Int J Surg 2017; 48: 105–9. doi: 10.1016/j.ijsu.2017.10.036 Epub 2017 Oct 20.

41 Tapia L F, Morse C R. Minimally invasive Ivor Lewis esophagectomy: description of a learning curve. J Am Coll Surg 2014; 218: 1130–40.

42 Mackenzie H, Markar S R, Askari A et al. National proficiency-gain curves for minimally invasive gastrointestinal cancer surgery. Br J Surg 2016; 103: 88–96.

43 van Workum F, Stenstra M H B C, Berkelmans G H K et al. Learning curve and associated morbidity of minimally invasive Esophagectomy: a retrospective Multicenter study. Ann Surg 2017. doi: 10.1097/SLA.0000000000002469 [Epub ahead of print].

44 Claassen L, van Workum F, Rosman C. Learning curve and postoperative outcomes of minimally invasive esophagectomy. J Thorac Dis 2019; 11: S777–85. doi: 10.21037/jtd.2018.12.54 Review.

45 Avery K N, Metcalfe C, Berrisford R et al. The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer—the ROMIO (randomized Oesophagectomy: minimally invasive or open) study: protocol for a randomized controlled trial. Trials 2014; 15: 200.

46 Metcalfe C, Avery K, Berrisford R et al. Comparing open and minimally invasive surgical procedures for oesophagectomy in the treatment of cancer: the ROMIO (randomised Oesophagectomy: minimally invasive or open) feasibility study and pilot trial. Health Technol Assess 2016; 20: 1–68.

47 Visser E, Markar S R, Ruurda J P, Hanna G B, van Hillegersberg R. Prognostic value of lymph node yield on overall survival in Esophageal cancer patients: a systematic review and meta-analysis. Ann Surg 2019; 269: 261–8. doi: 10.1097/SLA.0000000000002824.

48 Yilulaiwın W, Abulizi S, Ly H, Sun W. Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis. World J Surg Oncol 2016; 14: 304.

49 Seesing M F J, Gisbertz S S, Goense L et al. A propensity score matched analysis of open versus minimally invasive transthoracic Esophagectomy in the Netherlands. Ann Surg 2017; 266: 839–46. doi: 10.1097/SLA.0000000000002393.

50 van Workum F, Fransen L, Luyter M D, Rosman C. Learning curves in minimally invasive esophagectomy. World J Gastroenterol 2018; 24: 4974–8. doi: 10.3748/wjg.v24.i44.4974 Review.
### APPENDIX I—PRISMA checklist

| Section/topic                  | # | Checklist item                                                                 | Reported on page # |
|-------------------------------|---|----------------------------------------------------------------------------------|--------------------|
| **TITLE**                     |   | **Identify the report as a systematic review, meta-analysis, or both.**          | 1                  |
| **ABSTRACT**                  |   | **Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.** | 2                  |
| **INTRODUCTION**              |   | **Describe the rationale for the review in the context of what is already known.** | 3                  |
|                              |   | **Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).** | 3                  |
| **METHODS**                   |   | **Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.** | 4                  |
| Protocol and registration     | 5  | **Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.** | 4                  |
| Eligibility criteria          | 6  | **Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.** | 4                  |
| Information sources           | 7  | **Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.** | 4                  |
| Search                        | 8  | **State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).** | 4,5                |
| Data collection process       | 10 | **Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.** | 5                  |
| Data items                    | 11 | **List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.** | 5                  |
| Risk of bias in individual studies | 12 | **Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.** | 5                  |
| Summary measures              | 13 | **State the principal summary measures (e.g., risk ratio, difference in means).** | 6                  |
| Synthesis of results          | 14 | **Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.** | 6                  |
| Risk of bias across studies   | 15 | **Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).** | 6                  |
| Additional analyses           | 16 | **Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.** | 6                  |
| **RESULTS**                   |   | **Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.** | 7, Figure 1        |
| Study selection               | 17 | **For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.** | Table 1            |
| Study characteristics         | 18 | **Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).** | 7, online appendix |
| Risk of bias within studies   | 19 | **For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.** | 7,8, Figure 2, Table 2 |
| Results of individual studies | 20 | **Present results of each meta-analysis done, including confidence intervals and measures of consistency.** | 7-9, Table 2       |
| Synthesis of results          | 21 | **Present results of each meta-analysis done, including confidence intervals and measures of consistency.** | 7-9, Table 2       |
| Risk of bias across studies   | 22 | **Summarize the main findings including the strength of evidence for each main outcome, consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).** | 10                 |
| Summary of evidence           | 24 | **Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).** | 10                 |
| Conclusions                   | 26 | **Provide a general interpretation of the results in the context of other evidence, and implications for future research.** | 11,12              |
| Additional analysis           | 23 | **Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]).** | 8,9, Table 3-6     |

---

1. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
### APPENDIX II—Risk of bias assessment

| Study       | Representative | Selection | Ascertainment of exposure | Demonstration | Comparability | Outcome | Follow-up | Adequacy follow-up | Total stars |
|-------------|----------------|-----------|----------------------------|---------------|---------------|---------|-----------|---------------------|-------------|
| Berth 2018  | 1              | 1         | 1                          | 1             | 2             | 1       | 1         | 1                   | 9           |
| Bizekis 2006| 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Blazey 2011 | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Bonavina 2016| 1             | 0         | 1                          | 1             | 2             | 1       | 1         | 1                   | 8           |
| Daiko 2015  | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Elshaer 2017| 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Findlay 2017| 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Fumagalli 2019| 1           | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Grimminger 2018| 1        | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Hamouda 2009| 1              | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Kinjo 2012  | 1              | 0         | 1                          | 1             | 2             | 1       | 1         | 1                   | 8           |
| Kitagawa 2016| 1             | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Kubo 2014   | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Ichikawa 2013| 1             | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Lee 2011    | 1              | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Lee 2015    | 1              | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Li 2018     | 1              | 0         | 1                          | 1             | 2             | 1       | 1         | 1                   | 8           |
| Mao 2015    | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Martin 2005 | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Mu 2015     | 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Nilsson 2017| 1              | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Nozaki 2017 | 1              | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Oshikiri 2016| 1             | 0         | 1                          | 1             | 2             | 1       | 1         | 1                   | 8           |
| Safranek 2010| 1             | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Smithers 2007| 1             | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Souche 2019 | 1              | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Tsujimoto 2012| 1            | 1         | 1                          | 1             | 0             | 1       | 1         | 1                   | 7           |
| Yanasoot 2017| 1             | 0         | 1                          | 1             | 0             | 1       | 1         | 1                   | 6           |
| Yao 2017    |                |           |                             |               |               |         |           |                     |             |
APPENDIX III—Funnel plot for primary outcome parameter pneumonia
APPENDIX IV. Forest plots for parameters showing significant differences between hybrid and total MIE groups

Appendix IV figure 1: Main analysis including all HMIE versus all TMIE.

Appendix IV figure 1A - Wound infection

Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.

Appendix IV figure 1B - Operating time

Standardized mean difference (SMD) > 0 favors TMIE and SMD < 0 favors HMIE.
Appendix IV figure 1C – Blood loss

| Study or Subgroup | HMIE | TMIE | Std. Mean Difference IV, Random, 95% CI |
|-------------------|------|------|-------------------------------------|
| Berth 2018 LAO IL-IL | 450 | 237.5 | 40 | 325 | 150 | 20 | 4.9% | 0.58 [0.03, 1.13] |
| Blaza 2011 LAO | 250 | 4 | 142.2 | 16 | 445 | 134.7 | 6 | 4.1% | -1.33 [-2.37, -0.30] |
| Blaza 2011 LAO (by hospital stay analysis) | 300 | 0 | 228.4 | 67 | 221.5 | 152.9 | 35 | 5.1% | 0.52 [0.11, 0.94] |
| Bonavita 2016 LAO II-McK | 300 | 0 | 48.15 | 80 | 295 | 62.96 | 80 | 5.2% | 0.09 [0.22, 0.40] |
| Daiko 2015 TAO McK-McK | 498 | 0 | 1,048.25 | 33 | 286 | 283.25 | 31 | 5.0% | 0.27 [0.22, 0.76] |
| Ichikawa 2015 TAO McK-McK | 920 | 0 | 193.33 | 162 | 410 | 53.33 | 153 | 5.1% | 3.72 [0.36, 8.08] |
| Kinjo 2012 TAO McK-McK | 536 | 0 | 363.75 | 34 | 320 | 317.5 | 72 | 5.1% | 0.64 [0.23, 1.06] |
| Kitagawa 2016 LAO McK-McK | 430 | 0 | 267.5 | 45 | 150 | 164 | 60 | 5.1% | 1.30 [0.67, 1.72] |
| Kubo 2014 LAO McK-McK | 644 | 0 | 355 | 42 | 493 | 354 | 93 | 5.1% | 0.39 [0.03, 0.76] |
| Lee 2015 TAO III-IL | 465 | 0 | 323.3 | 44 | 460 | 355.5 | 30 | 5.0% | 0.01 [-0.45, 0.48] |
| Lee 2015 TAO III-IL | 374.8 | 0 | 94 | 4 | 44 | 349.8 | 77.4 | 54 | 5.1% | 0.29 [-0.11, 0.69] |
| LJ 2015 TAO McK-McK | 329.8 | 0 | 233.8 | 86 | 229.1 | 210.8 | 86 | 5.2% | 0.45 [0.15, 0.75] |
| Ma 2015 TAO and LAO McK-McK | 300 | 0 | 148.15 | 70 | 100 | 74.07 | 375 | 5.2% | 2.23 [1.43, 3.03] |
| Nozaki 2017 TAO McK-McK | 1,231.7 | 0 | 1,056.25 | 43 | 649.25 | 592.25 | 58 | 5.1% | 0.76 [0.33, 1.14] |
| Oshikawa 2016 TAO McK-McK | 206 | 0 | 102 | 32 | 120 | 49 | 32 | 4.9% | 1.06 [0.54, 1.59] |
| Smithers 2007 TAO McK-McK | 400 | 0 | 250 | 309 | 300 | 248.25 | 23 | 5.1% | 0.49 [0.13, 0.82] |
| Souza 2019 LAO III-IL | 190 | 0 | 95 | 79 | 135.5 | 70 | 50 | 5.2% | 0.69 [0.34, 1.03] |
| Tsujimoto 2012 LAO III-Mix | 544 | 0 | 365 | 27 | 373 | 388 | 22 | 4.9% | 0.65 [0.12, 1.02] |
| Yanase 2017 TAO McK-McK | 349.83 | 0 | 96.84 | 16 | 246.15 | 24.97 | 13 | 4.5% | 1.24 [0.42, 2.05] |
| Yao 2017 TAO McK-McK | 150 | 0 | 37.03 | 71 | 100 | 27.407 | 61 | 5.1% | 1.51 [1.12, 1.90] |

Heterogeneity: Tau² = 0.95, Chi² = 424.00, df = 19 (P < 0.00001), I² = 96%
Test for overall effect: Z = 3.49 (P = 0.0005)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE
Appendix IV figure 2A – Pneumonia

| Study or Subgroup | HMI | Total | TMIE | Total | Weight | Risk Ratio |
|-------------------|-----|-------|------|-------|--------|------------|
|                   | Events |       | Events |       |        | M-H, Random, 95% CI | M, Random, 95% CI |
| Berlh 2018 LAO IL-IL | 11 | 40 | 1 | 20 | 8.6% | 5 | [0.76, 3.66] |
| Bizekis 2006 LAO IL-IL | 4 | 35 | 0 | 15 | 4.2% | 4 | [0.23, 0.97] |
| Grimminger 2018 LAO IL-IL | 7 | 25 | 3 | 25 | 20.7% | 2.33 | [0.68, 8.01] |
| Kitagawa 2016 LAO McK-McK | 6 | 45 | 5 | 60 | 24.4% | 1.60 | [0.52, 4.91] |
| Souche 2019 LAO IL-IL | 6 | 79 | 6 | 59 | 26.1% | 0.73 | [0.25, 2.16] |
| Tsujimoto 2012 LAO IL-Mix | 9 | 27 | 2 | 22 | 15.9% | 3.67 | [0.88, 15.25] |
| **Total (95% CI)** | 251 | 200 | 100% | 1.86 | [1.03, 3.37] |

Relative risk (RR) > 1 favors TMIE and RR<1 favors HMI.

Appendix IV figure 2B – Extracted lymph nodes

| Study or Subgroup | HMI | SD Total | TMIE | SD Total | Weight | Std. Mean Difference |
|-------------------|-----|---------|------|---------|--------|---------------------|
|                   | IV, Random, 95% CI | IV, Random, 95% CI |
| Berlh 2018 LAO IL-IL | 38.25 | 9.25 | 40 | 31.25 | 6.75 | 20 | 8.2% | 0.58 | [0.03, 1.13] |
| Bizekis 2011 LAO | 34.7 | 12.9 | 16 | 25 | 8.8 | 6 | 3.4% | 0.78 | [0.19, 1.75] |
| Blazely2 LAO (bth hospital stay analyse) | 25.3 | 7.9 | 67 | 20 | 6.9 | 35 | 11.2% | 0.63 | [0.21, 1.05] |
| Bonavina 2016 LAO II-McK | 34 | 12.59 | 60 | 32 | 10.37 | 80 | 14.5% | 0.17 | [0.04, 0.49] |
| Elshaer 2017 LAO IL-IL | 25.25 | 8.25 | 11 | 23.5 | 6 | 15 | 4.9% | 0.24 | [0.54, 1.02] |
| Findlay 2017 LAO IL-McK | 31.5 | 14.75 | 95 | 22.75 | 9.25 | 67 | 14.1% | 0.68 | [0.36, 1.00] |
| Grimminger 2018 LAO IL-IL | 26.2 | 12.4 | 25 | 26 | 9.4 | 26 | 9.1% | 0.11 | [0.45, 0.66] |
| Kitagawa 2016 LAO McK-McK | 40 | 16.5 | 45 | 40 | 18.75 | 60 | 12.1% | 0.00 | [0.39, 0.99] |
| Lee 2011 LAO McK-McK | 14.64 | 8.8 | 44 | 13.97 | 7.7 | 30 | 10.0% | 0.08 | [0.39, 0.54] |
| Souchie 2019 LAO IL-IL | 19 | 8.5 | 79 | 19 | 9 | 58 | 13.5% | 0.00 | [0.34, 0.34] |
| **Total (95% CI)** | 502 | 396 | 100% | 0.29 | [0.10, 0.49] |

Standardized mean difference (SMD) >0 favors HMI and SMD <0 favors TMIE.

Appendix IV figure 2C – Operative time

| Study or Subgroup | HMI | Mean | SD | Total | TMIE | SD | Total | Weight | Std. Mean Difference |
|-------------------|-----|------|----|-------|------|----|-------|--------|---------------------|
|                   | IV, Random, 95% CI | IV, Random, 95% CI |
| Berlh 2018 LAO IL-IL | 241.75 | 56.75 | 40 | 356.75 | 68.75 | 20 | 8.9% | -0.25 | [-0.80, 0.30] |
| Bizekis 2011 LAO | 413.1 | 50.6 | 16 | 595 | 56.1 | 8 | 2.6% | -3.18 | [-4.58, -1.78] |
| Blazely2 LAO (bth hospital stay analyse) | 362 | 71.7 | 67 | 370.1 | 65.1 | 35 | 10.7% | -0.12 | [-0.52, 0.29] |
| Bonavina 2016 LAO II-McK | 390 | 50.37 | 80 | 330 | 48.99 | 60 | 12.1% | -0.60 | [-0.82, -0.28] |
| Elshaer 2017 LAO IL-IL | 399 | 47.8 | 11 | 349 | 46.6 | 15 | 5.7% | -0.82 | [-1.64, -0.01] |
| Grimminger 2018 LAO IL-IL | 314.3 | 43.4 | 25 | 338.8 | 52.1 | 25 | 8.4% | -0.50 | [-1.07, 0.06] |
| Kitagawa 2018 LAO McK-McK | 570 | 90 | 45 | 609 | 92.25 | 60 | 11.0% | -0.42 | [-0.81, -0.03] |
| Kubo 2014 LAO McK-McK | 556 | 126 | 42 | 579 | 89 | 93 | 11.3% | -0.22 | [-0.59, 0.14] |
| Lee 2011 LAO McK-McK | 587.16 | 126.61 | 44 | 621.67 | 83.11 | 30 | 9.4% | -1.02 | [-1.51, 0.57] |
| Souchie 2019 LAO IL-IL | 326.75 | 68.25 | 79 | 363.5 | 83.5 | 59 | 11.7% | -0.49 | [-0.83, -0.14] |
| Tsujimoto 2012 LAO IL-Mix | 476 | 110 | 27 | 472 | 89 | 22 | 8.4% | 0.04 | [-0.52, 0.60] |
| **Total (95% CI)** | 476 | 444 | 100% | -0.50 | [-0.74, 0.25] |

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMI.
Appendix IV figure 2D – Blood loss

| Study or Subgroup | HME Mean | SD | Total | HME Total | Mean | SD | Total | Mean | SD | Total | Std. Mean Difference IV, Random, 95% CI |
|-------------------|---------|----|-------|---------|-------|----|-------|-------|----|-------|-----------------------------------|
| Berth 2018 LAO IL-IL | 450 | 237.5 | 40 | 325 | 150 | 20 | 10 | 10.4 | 0.58 (0.03, 1.13) |
| Blazebey 2011 LAO | 250.4 | 142.2 | 16 | 445 | 134.7 | 6 | 5.9 | 0.13 (0.25, -0.03) |
| Blazebey 2011 LAO (by hospital stay analysis) | 330.3 | 226.4 | 67 | 221.5 | 152.9 | 35 | 12.0 | 0.53 (0.11, 0.94) |
| Bonavina 2016 LAO III-McK | 300 | 48.15 | 80 | 295 | 62.96 | 80 | 13.1 | 0.09 (-0.22, 0.40) |
| Kitagawa 2016 LAO III-McK | 430 | 287.5 | 45 | 150 | 164 | 60 | 11.8 | 0.30 (0.87, 1.72) |
| Kubo 2014 LAO McK-McK | 344 | 355 | 42 | 493 | 394 | 93 | 12.6 | 0.39 (0.03, 0.76) |
| Lee 2011 LAO McK-McK | 345 | 323.3 | 44 | 480 | 355.5 | 30 | 11.4 | 0.01 (-0.45, 0.46) |
| Sorensen 2019 LAO IL-IL | 190 | 85 | 79 | 135.5 | 70 | 58 | 12.7 | 0.69 (0.34, 1.03) |
| Tsujimoto 2012 LAO III-Mix | 544 | 365 | 27 | 373 | 388 | 22 | 10.2 | 0.45 (-0.12, 1.02) |
| Total (95% CI) | 440 | 404 | 100.0% | 39 | 0.39 (0.07, 0.72) |

Heterogeneity: Tau² = 0.19; Chi² = 37.39, df = 9 (P < 0.00001); I² = 79%
Test for overall effect Z = 2.40 (P = 0.02)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE

Appendix IV figure 3A – All complications

| Study or Subgroup | HME Events | M-H Events | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------|------------|--------------------------------|
| Daiko 2015 TAO McK-McK | 12 | 33 | 1.13 [0.57, 2.23] |
| Ichikawa 2013 TAO McK-McK | 117 | 162 | 1.18 [1.00, 1.38] |
| Kinjo 2012 TAO McK-McK | 20 | 34 | 1.25 [0.86, 1.81] |
| Smithers 2007 TAO McK-McK | 193 | 309 | 1.03 [0.73, 1.44] |
| Total (95% CI) | 538 | 279 | 1.16 [1.02, 1.32] |

Total events: 342, 152
Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 3 (P = 0.88); I² = 0%
Test for overall effect Z = 2.20 (P = 0.03)

Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.

Appendix IV figure 3B – Blood loss

| Study or Subgroup | HME Mean | SD | Total | HME Total | Mean | SD | Total | Mean | SD | Total | Std. Mean Difference IV, Random, 95% CI |
|-------------------|---------|----|-------|---------|-------|----|-------|-------|----|-------|-----------------------------------|
| Daiko 2015 TAO McK-McK | 498 | 1,049.25 | 33 | 286 | 283.25 | 31 | 10.0 | 0.27 [0.22, 0.76] |
| Ichikawa 2013 TAO McK-McK | 920 | 183.33 | 162 | 410 | 53.33 | 153 | 10.2 | 3.72 [3.36, 4.09] |
| Kinjo 2012 TAO McK-McK | 536 | 363.75 | 34 | 320 | 317.56 | 72 | 10.1 | 0.64 [0.23, 1.06] |
| Lee 2015 LAO III-IL | 374.8 | 944 | 44 | 349.8 | 77.4 | 54 | 10.1 | 0.29 [0.11, 0.89] |
| Li 2018 TAO McK-McK | 329.8 | 233.8 | 86 | 229.1 | 210.8 | 86 | 10.3 | 0.45 [0.15, 0.75] |
| Nozaki 2017 TAO McK-McK | 1,231.75 | 1,056.25 | 43 | 689.25 | 502.5 | 58 | 10.1 | 0.72 [0.33, 1.14] |
| Oshikiri 2016 TAO McK-McK | 206 | 182 | 32 | 120 | 49 | 32 | 9.9 | 1.06 [0.54, 1.59] |
| Smithers 2007 TAO McK-McK | 400 | 250 | 309 | 300 | 246.25 | 23 | 10.1 | 0.40 [0.03, 0.82] |
| Yanasoot 2017 TAO McK-McK | 340.63 | 96.84 | 16 | 246.15 | 24.97 | 13 | 9.2 | 1.24 [0.43, 2.05] |
| Yao 2017 TAO McK-McK | 150 | 37.03704 | 71 | 100 | 27.40741 | 60 | 10.1 | 1.51 [1.12, 1.90] |
| Total (95% CI) | 830 | 582 | 100.0% | 1.83 [0.31, 1.75] |

Heterogeneity: Tau² = 1.30; Chi² = 263.17, df = 9 (P < 0.00001); I² = 97%
Test for overall effect Z = 2.81 (P = 0.005)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE
Appendix IV figure 4A – Anastomotic leakage

| Study or Subgroup | HMIE Events | TMIE Events | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|-------------|-------------|--------|--------------------------------|
| Berth 2018 LAO IL-IL | 2          | 40         | 3      | 20 | 4.7% | 0.33 [0.06, 1.84] |
| Bizekis 2006 LAO IL-IL | 3          | 35         | 0      | 15 | 1.6% | 3.11 [0.17, 56.77] |
| Elshaer 2017 LAO IL-IL | 2          | 11         | 3      | 15 | 5.2% | 0.91 [0.18, 4.55] |
| Fumagali 2019 LAO IL-IL | 22        | 244        | 21     | 105 | 44.4% | 0.45 [0.26, 0.78] |
| Grimminger 2018 LAO IL-IL | 1         | 25         | 4      | 25 | 3.0% | 0.25 [0.03, 2.08] |
| Hamsoula 2013 LAO IL-IL | 3          | 25         | 1      | 26 | 2.9% | 3.12 [0.35, 28.03] |
| Souchie 2019 LAO IL-IL | 15         | 79         | 18     | 58 | 30.2% | 0.61 [0.34, 1.11] |

Total (95% CI) 459 264 100.0% 0.55 [0.38, 0.80]

Total events 49 50

Heterogeneity: Tau² = 0.00, Chi² = 5.66, df = 6 (P = 0.46); P = 0%
Test for overall effect: Z = 3.14 (P = 0.002)

Relative risk (RR) > 1 favors TMIE and RR<1 favors HMIE.

Appendix IV figure 4B – Wound infection

| Study or Subgroup | HMIE Events | TMIE Events | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|-------------|-------------|--------|--------------------------------|
| Grimminger 2018 LAO IL-IL | 4         | 25         | 0      | 25 | 33.5% | 9.00 [0.51, 158.85] |
| Souchie 2019 LAO IL-IL | 9          | 79         | 1      | 58 | 66.5% | 6.61 [0.86, 50.71] |

Total (95% CI) 104 83 100.0% 7.33 [1.39, 38.61]

Total events 13 1

Heterogeneity: Tau² = 0.00, Chi² = 0.03, df = 1 (P = 0.86); P = 0%
Test for overall effect: Z = 2.35 (P = 0.02)

Relative risk (RR) > 1 favors TMIE and RR<1 favors HMIE.

Appendix IV figure 4C – Operating time

| Study or Subgroup | HMIE Mean | SD | Total | Mean | SD | Total | Mean | SD | Total |
|-------------------|-----------|----|-------|------|----|-------|------|----|-------|
| Berth 2018 LAO IL-IL | 341.75 | 56.75 | 40 | 356.75 | 56.75 | 20 | 293.9 | 56.75 | 10 |
| Elshaer 2017 LAO IL-IL | 309 | 47.8 | 11 | 349 | 46.6 | 15 | 397.1 | 46.6 | 5 |
| Grimminger 2018 LAO IL-IL | 314.3 | 43.4 | 25 | 338.8 | 52.1 | 25 | 393.0 | 52.1 | 5 |
| Souchie 2019 LAO IL-IL | 326.75 | 68.25 | 79 | 363.5 | 83.5 | 58 | 401.1 | 83.5 | 5 |

Total (95% CI) 155 118 100.0% -0.47 [-0.72, -0.23]

Heterogeneity: Tau² = 0.00, Chi² = 3.22, df = 3 (P = 0.72); P = 0%
Test for overall effect: Z = 3.77 (P = 0.0002)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.

Appendix IV figure 4D – Blood loss

| Study or Subgroup | HMIE SD | SD | Total | Mean | SD | Total | Mean | SD | Total |
|-------------------|--------|----|-------|------|----|-------|------|----|-------|
| Berth 2018 LAO IL-IL | 450 | 237.5 | 40 | 325 | 150 | 20 | 289.9 | 150 | 10 |
| Souchie 2019 LAO IL-IL | 190 | 65 | 79 | 135.5 | 70 | 58 | 71.1 | 70 | 5 |

Total (95% CI) 119 78 100.0% 0.66 [0.36, 0.95]

Heterogeneity: Tau² = 0.00, Chi² = 0.10, df = 1 (P = 0.75); P = 0%
Test for overall effect: Z = 4.37 (P = 0.0001)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.
**Appendix IV figure 5A – Pulmonary complications**

| Study or Subgroup | HIME Events | Total | TMIE Total | Weight | Risk Ratio M-H, Random, 95% CI |
|-------------------|-------------|-------|------------|--------|--------------------------------|
| Daiko 2015 TAO McK-McK | 0 | 33 | 30 | 31 | Not estimable |
| Ichikawa 2013 TAO McK-McK | 33 | 162 | 20 | 153 | 23.9% | 1.56 [0.94, 2.59] |
| Kinjo 2012 TAO McK-McK | 13 | 34 | 9 | 72 | 14.0% | 3.06 [1.45, 6.45] |
| Kubo 2014 LAO McK-McK | 5 | 42 | 8 | 93 | 7.9% | 1.30 [0.48, 3.90] |
| Lee 2011 LAO McK-McK | 9 | 44 | 2 | 30 | 4.4% | 3.07 [0.71, 13.21] |
| Li 2018 TAO McK-McK | 18 | 86 | 12 | 86 | 16.6% | 1.50 [0.77, 2.92] |
| Mu 2015 TAO and LAO McK-McK | 2 | 70 | 11 | 375 | 4.3% | 0.97 [0.22, 4.30] |
| Smithers 2007 TAO McK-McK | 98 | 309 | 8 | 23 | 20.1% | 0.91 [0.51, 1.63] |
| Yao 2017 TAO McK-McK | 7 | 71 | 7 | 60 | 8.8% | 0.85 [0.31, 2.27] |

Total (95% CI) 851 923 100.0% 1.45 [1.05, 1.99]

Total events 185 77

Heterogeneity: $I^2 = 0.04$; $Q = 8.83$, df = 7 ($P = 0.27$); $P = 21$

Test for overall effect $Z = 2.29$ ($P = 0.02$)

Relative risk (RR) > 1 favors TMIE and RR<1 favors HIME.

**Appendix IV figure 5B – Hospital length of stay**

| Study or Subgroup | HIME Mean | SD | Total Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI |
|-------------------|-----------|----|------------|----|--------|--------|----------------------------------------|
| Daiko 2015 TAO McK-McK | 19 | 9.5 | 33 | 20 | 16.5 | 31 | 8.3% | -0.07 [-0.56, 0.42] |
| Kinjo 2012 TAO McK-McK | 32 | 23.5 | 34 | 23 | 14.5 | 72 | 8.9% | 0.41 [0.00, 0.83] |
| Kitagawa 2016 LAO McK-McK | 35 | 23.5 | 45 | 16.5 | 33.5 | 60 | 9.1% | 0.82 [0.22, 1.42] |
| Kubo 2014 LAO McK-McK | 33 | 16 | 42 | 32.3 | 23 | 93 | 9.3% | 0.03 [-0.33, 0.40] |
| Lee 2011 LAO McK-McK | 42.75 | 30.19 | 44 | 23.45 | 13.58 | 30 | 0.4% | 0.77 [0.29, 1.25] |
| Li 2016 TAO McK-McK | 21.8 | 9.9 | 80 | 21.2 | 12.9 | 68 | 0.0% | 0.03 [-0.26, 0.33] |
| Mu 2015 TAO and LAO McK-McK | 18 | 8.15 | 70 | 18 | 7.41 | 375 | 10.1% | 0.27 [0.01, 0.53] |
| Oshikawa 2016 TAO McK-McK | 20 | 19.75 | 32 | 19 | 17.75 | 32 | 8.3% | 0.05 [-0.44, 0.54] |
| Saltman 2014 LAO and TAO McK-McK | 12.89 | 10.5 | 34 | 11 | 9.5 | 41 | 8.6% | 0.19 [-0.27, 0.64] |
| Smithers 2007 TAO McK-McK | 13 | 19.17 | 369 | 11 | 10.5 | 23 | 8.8% | 0.11 [-0.32, 0.53] |
| Yanasost 2017 TAO McK-McK | 19.65 | 2.041 | 16 | 5.48 | 0.12 | 13 | 1.1% | 0.95 [0.64, 1.16] |
| Yao 2017 TAO McK-McK | 11 | 1.481481 | 71 | 10 | 1.481481 | 60 | 9.4% | 0.57 [0.32, 1.02] |

Total (95% CI) 816 916 100.0% 0.38 [0.09, 0.66]

Heterogeneity: $I^2 = 0.20$; $Q = 63.19$, df = 11 ($P = 0.00001$); $P = 63$

Test for overall effect $Z = 2.56$ ($P = 0.01$)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HIME.

**Appendix IV figure 5C – Blood loss**

| Study or Subgroup | HIME Mean | SD | Total Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI |
|-------------------|-----------|----|------------|----|--------|--------|----------------------------------------|
| Daiko 2015 TAO McK-McK | 498 | 1,049.25 | 33 | 286 | 282.25 | 31 | 9.3% | 0.27 [0.22, 0.76] |
| Ichikawa 2013 TAO McK-McK | 920 | 183.33 | 162 | 410 | 533.33 | 153 | 8.5% | 3.72 [3.36, 4.09] |
| Kinjo 2012 TAO McK-McK | 536 | 382.75 | 34 | 220 | 317.5 | 72 | 8.4% | 0.64 [0.23, 1.06] |
| Kitagawa 2016 LAO McK-McK | 430 | 267.5 | 45 | 150 | 164 | 60 | 8.4% | 1.30 [0.87, 1.72] |
| Kubo 2014 LAO McK-McK | 644 | 355 | 42 | 493 | 394 | 93 | 8.5% | 0.39 [0.03, 0.76] |
| Lee 2011 LAO McK-McK | 465 | 323.3 | 44 | 480 | 355.5 | 30 | 8.3% | 0.01 [-0.45, 0.46] |
| Li 2016 TAO McK-McK | 329.8 | 233.8 | 80 | 229.1 | 210.8 | 66 | 8.5% | 0.45 [0.15, 0.75] |
| Mu 2015 TAO and LAO McK-McK | 300 | 148.15 | 70 | 100 | 74.07 | 375 | 0.5% | 2.22 [1.93, 2.52] |
| Oshikawa 2016 TAO McK-McK | 206 | 192 | 32 | 120 | 49 | 32 | 8.2% | 1.06 [0.54, 1.59] |
| Smithers 2007 TAO McK-McK | 400 | 250 | 209 | 300 | 248.25 | 23 | 8.3% | 0.40 [-0.03, 0.82] |
| Yanasost 2017 TAO McK-McK | 340.63 | 96.84 | 16 | 246.15 | 24.97 | 13 | 7.8% | 1.24 [-0.43, 2.06] |
| Yao 2017 TAO McK-McK | 150 | 37.03703 | 71 | 100 | 27.40741 | 60 | 9.4% | 1.51 [0.11, 2.90] |

Total (95% CI) 944 1028 100.0% 0.11 [0.46, 1.75]

Heterogeneity: $I^2 = 1.25$; $Q = 332.83$, df = 11 ($P = 0.00001$); $P = 97$

Test for overall effect $Z = 3.39$ ($P = 0.0008$)

Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HIME.
APPENDIX IV-A: MAIN ANALYSIS
INCLUDING ALL HMIE VERSUS ALL TMIE

1. Wound infection
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
2. Operating time
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.
3. Blood loss
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.

APPENDIX IV-B: SUBGROUP ANALYSIS
INCLUDING LAPAROSCOPY-ASSISTED HYBRID MINIMALLY INVASIVE ESOPHAGECTOMY VERSUS TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY

1. Pneumonia
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
2. Extracted lymph nodes
   Standardized mean difference (SMD) >0 favors HMIE and SMD <0 favors TMIE.
3. Operative time
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.
4. Blood loss
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.

APPENDIX IV-C: SUBGROUP ANALYSIS
INCLUDING THORACOSCOPY-ASSISTED HYBRID MINIMALLY INVASIVE ESOPHAGECTOMY VERSUS TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY

1. All complications
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
2. Blood loss
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.

APPENDIX IV-D: SUBGROUP ANALYSIS
INCLUDING LAPAROSCOPY-ASSISTED HYBRID MINIMALLY INVASIVE IVOR LEWIS ESOPHAGECTOMY VERSUS TOTALLY MINIMALLY INVASIVE IVOR LEWIS ESOPHAGECTOMY

1. Anastomotic leakage
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
2. Wound infection
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
3. Operating time
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.
4. Blood loss
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.

APPENDIX IV-E: SUBGROUP ANALYSIS
INCLUDING HYBRID MINIMALLY INVASIVE MCKEOWN ESOPHAGECTOMY VERSUS TOTALLY MINIMALLY INVASIVE MCKEOWN ESOPHAGECTOMY

1. Pulmonary complications
   Relative risk (RR) > 1 favors TMIE and RR < 1 favors HMIE.
2. Hospital length of stay
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.
3. Blood loss
   Standardized mean difference (SMD) >0 favors TMIE and SMD <0 favors HMIE.